Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation : A proof of concept

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 264(2024) vom: 28. Juni, Seite 110240
1. Verfasser: Favi, Evaldo (VerfasserIn)
Weitere Verfasser: Cresseri, Donata, Perego, Marta, Ikehata, Masami, Iesari, Samuele, Campise, Maria Rosaria, Morello, William, Testa, Sara, Sioli, Viviana, Mattinzoli, Deborah, Longhi, Elena, Del Gobbo, Alessandro, Castellano, Giuseppe, Ferraresso, Mariano
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Case Reports Antibody-mediated rejection Eculizumab Immunosuppression Kidney transplant Obinutuzumab Treatment eculizumab A3ULP0F556 mehr... Antibodies, Monoclonal, Humanized obinutuzumab O43472U9X8 Complement C5 Antigens, CD20 Complement Inactivating Agents Isoantibodies